Plate VIII · The colophon
About this BPC-157 TB-500 field-record.
An independent editorial project that presses the published research on the Wolverine blend into a labeled, cited record — with its regulatory status read first.
What this site is
Wolverine Prescribed is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 "Wolverine" blend. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The approach is a naturalist's field-record. The Wolverine blend is two distinct peptides, so we mount them as two specimens — a 15-residue body-protection compound beside a 7-residue actin-binding fragment — each with its label, its citation, and its caveat written in the margin. Where the literature is firm, we say so plainly. Where it stops, we mark the gap and leave it visible.
On the word "prescribed" in the name
The word "prescribed" in this domain is editorial framing, not a claim about services. It signals the regulatory and formulary register — who studies the pairing, how compounded access is actually regulated, and where each constituent sits on the FDA record. It does not mean a doctor staffs this site, that consultations are offered, or that prescriptions are written or filled here. No medical professional is implied, named, or invented anywhere on these pages, and nothing here is for sale.
That framing is deliberate, because this subject invites overreach. The Wolverine pairing is discussed in athlete forums as a cure-all for any injury. The published record is narrower and more honest: preclinical, single-compound, largely from animal models, with no controlled study of the combination [9]. The most useful thing a site like this can do is read the regulatory status first and keep the science to its record.
How we handle sources
Every quantitative claim on this site is tied to a numbered citation in the references register, resolving to a PubMed entry, a DOI, or an FDA page. We draw on the foundational peptide literature — the transected-tendon BPC-157 result [1], the VEGFR2 angiogenesis work [2], the G-actin crystal structure [3] — on the pharmacokinetic record for each constituent [5][6][7], and on recent reviews that bound the evidence, including a 2025 systematic review [9] and a 2026 Sports Medicine review [10].
We are deliberate about what we do not do. We do not aggregate forum protocols, we do not report a community "loading" schedule as if it were a finding, and we do not soften the two structural caveats — the fragment-versus-full-protein provenance gap and the absence of any controlled combination study [4][9]. Regulatory facts are kept separate and conservative: we state present-tense status cited to FDA, and we never present a possible future decision as settled. The result is a digest you can audit line by line — a record, not a recommendation.